Drug lipophilicity is a core property that contributes to drug solubility, permeability, metabolic disposition, and other key properties. Take a deeper look into how drug lipophilicity has evolved over time, its impact on drug development, and the need for new technology to enable new more complex drugs.
Optimizing a drug’s solid form can improve its solubility and bioavailability when further molecular modifications are prohibitive. The Nanoform team reviews solid form strategies for increasing the solubility and oral bioavailability of small molecule drugs.
Glioblastoma multiforme (GBM) is the most common type of malignant primary brain tumor. It is difficult to treat and has a high risk of recurrence after surgery, placing efficacious treatments in high demand. Discover new possibilities for increased dosing capabilities and diffusion across the brain parenchyma offered by nanoformed APIs.
Christian Jones, CCO of Nanoform, discusses what it truly means to be patient-centric in the modern pharmaceutical industry. Discover the challenges pharma companies are facing as they switch focus, as well as the actions and technologies companies are implementing to help achieve a brighter future for patients.
Nanoform’s proprietary bionanoparticle technology can deliver large molecule drug particles as small as 50 nm while retaining biological activity. This can not only enable more patient-friendly approaches to drug delivery, but also potentially higher loads of active ingredients.
